



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	385069	QUADRACEL 0.5mL injection prefilled syringe
<b>ARTG entry for</b>	Medicine Registered	
<b>Sponsor</b>	Sanofi-Aventis Australia Pty Ltd	
<b>Postal Address</b>	Locked Bag 2227, NORTH RYDE BC, NSW, 1670 Australia	
<b>ARTG Start Date</b>	24/05/2022	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Drug Safety Evaluation Branch	

### Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Except where the sponsor has been contracted by an overseas party to manufacturer the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods, and upon the request of the Head, Office of Prescription Medicines Authorisation Branch, Therapeutic Goods Administration, shall produce such evidence to this officer.

The conditions applying to these goods when they are exported from Australia are given below:

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

The therapeutic goods grouped in this registration/listing as export only goods under the following names are included in the Australian Register of Therapeutic Goods and may not be supplied in Australia. Export Name(s) to be added:

### Products

#### 1 . QUADRACEL 0.5mL injection prefilled syringe

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	15/03/2024
---------------------	-------------------------	-----------------------	------------

#### Permitted Indications

No Permitted Indications included on Record

#### Indication Requirements

No Indication Requirements included on Record

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

Quadracel is indicated for primary immunisation of children from the age of 2 months to 12 months against diphtheria, tetanus, pertussis, and poliomyelitis. Quadracel is also indicated for the fourth dose for children from 15 months to six years of age who have been immunised previously with three doses of diphtheria, tetanus, pertussis and polio vaccines.

#### Warnings

See Product Information and Consumer Medicine Information for this product

#### Additional Product information

#### Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Syringe	Glass Type I Clear	36 Months	Store at 2 to 8 degrees Celsius	Neither child resistant closure nor restricted	Do not Freeze



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

flow insert

**Pack Size/Poison information**

**Pack Size**

10 monodose prefilled syringes

**Poison Schedule**

(S4) Prescription Only Medicine

**Components**

**1 . Medicine Component**

<b>Dosage Form</b>	Injection, suspension
<b>Route of Administration</b>	Intramuscular
<b>Visual Identification</b>	Sterile, uniform, cloudy, white to off-white suspension

**Active Ingredients**

Diphtheria toxoid	30 IU
Pertactin	3 microgram
Pertussis filamentous haemagglutinin	20 microgram
Pertussis fimbriae 2 + 3	5 microgram
Pertussis toxoid	20 microgram
Poliovirus	29 DAgU
Poliovirus	26 DAgU
Poliovirus	7 DAgU
Tetanus toxoid	40 IU

**Other Ingredients (Excipients)**

aluminium phosphate  
bovine serum albumin  
formaldehyde  
glutaral  
neomycin  
phenoxyethanol  
polymyxin B sulfate  
polysorbate 80  
water for injections

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.